Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from HIMS

IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.

Investors Business Daily

4 Stocks That Crushed Analyst Estimates by More Than Double

Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.

MarketBeat

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick

Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.

MarketBeat

3 Digital Health Companies Enhancing Patient Engagement

The digital health industry has experienced impressive growth, driven by rising healthcare demands, digitalization, and technological innovations. Amid this, Hims & Hers Health (HIMS), GoodRx Holdings (GDRX), and Talkspace (TALK) are strategically positioned to thrive in the sector, making them attractive investment opportunities. Read on….

StockNews.com

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.

Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Spotlight on Hims & Hers Health: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Hims Hers Health (NYSE:HIMS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HIMS usually suggests something big…

Benzinga

IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory

Hims stock jumped early Tuesday after the online pharmacy beat expectations, helped by Hims & Hers' weight-loss drug.

Investors Business Daily

Hims & Hers Health Tops Growth 50 List As FDA OKs Cheaper Weight-Loss Drug

Hims stock is near its all time high and a buy point of 25.74.

Investors Business Daily

Hims & Hers Shares Rallied 22% Over Two Days. Why That Move Is Now At Risk.

Hims stock rallied almost 22% over two days on enthusiasm after the FDA said it will allow compounded versions of Lilly's obesity drug.

Investors Business Daily

Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

Investors Business Daily

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Hims & Hers is a digital health company that is firing on all cylinders, while improving its profit margins at a robust pace.

Barchart

After Doubling in the Past 6 Months, Will Hims & Hers Health Stock Continue Higher?

Telehealth company Hims & Hers is trading near record highs after issuing strong guidance for the full year ahead. With the stock up nearly 145% in the last six months, how much more upside is left for HIMS?

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Subscription-based care moves beyond peddling birth control and helping with hair loss

Online, direct-to-consumer health care has grown well beyond its roots mostly treating hair loss and acne or selling birth control pills

The Hindu

HIMS Associate Professor, earlier suspended on charges of misconduct, appointed District Surgeon in Hassan

Dr. H.C. Lokesh appointed District Surgeon of Sri Chamarajendra Hospital in Hassan after being reinstated in August 2022.

The Hindu

MBBS classes will start in new building of Haveri Institute of Medical Sciences, says Minister Shivanand Patil

Minister for Textiles, Sugarcane Development and Sugar and district-in-charge for Haveri Shivanand Patil announced that the classes of the first year MBBS course would be held at the new building of Haveri Institute of Medical Sciences and Hospital from September.

Broadcasting & Cable

Fubo’s Maximum Effort Channel Brings Back ALF in Series, Branded Content

Mint Mobile, Fubo, Hims, MNTN, Ring get messages from Paul Fusco’s furry alien

Get all your
news in one place.

100’s of premium titles.
One news app.

The Hindu

Tension at NICU in Hassan Institute of Medical Sciences after stabiliser blast

Tension prevailed in the Neonatal Intensive Care Unit (NICU) of the Hassan Institute of Medical Sciences (HIMS) in Hassan on Sunday when smoke covered the premises broke out following a stabiliser blast.

StockNews.com

Insider Trading Picking Up For HIMS, Should You Buy?

Shares of multi-specialty healthcare company Hims & Hers Health (HIMS) gained more than 25% over the past month, with increased insider trading sparking investor interest. However, given its bleak financials, is the stock a buy now? Read more to find out.

StockNews.com

After Plummeting from Covid-Induced Highs, is Now a Good Time to Scoop Up Telehealth Stocks?

Telehealth stocks have declined from the Covid-induced highs and are expected to plunge further due to the nation’s return to normalcy. Moreover, the current macroeconomic headwinds are expected to put added pressure on telehealth companies Teladoc Health (TDOC), American Well (AMWL), Hims & Hers Health (HIMS), iRhythm Technologies (IRTC), and…

Benzinga

Hims & Hers Health's Return On Capital Employed Overview

According to Benzinga Pro data, during Q1, Hims & Hers Health (NYSE:HIMS) posted sales of $101.31 million. Earnings were up 47.85%, but Hims & Hers Health still reported an overall loss of $16.25 million.

StockNews.com

3 SPAC Stocks Down More Than 60% Since Going Public

The Federal Reserve's interest rate increases to reduce inflationary pressure, and recession fears, have driven many SPAC stocks to significant price declines of late. The shares of Hims & Hers Health (HIMS), Clover Health Investments (CLOV), and BARK (BARK) have retreated more than 60% since these companies went public via…

HIMS graduation ceremony

Hassan

1 2

People

Donald Trump

80,914 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.